Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pfizer"

25 mentions found

Social media posts have suggested that the contents of the vaccines for COVID-19 are not known, because the virus that causes the disease has not been isolated. An undated photo shows a 3-D print of a SARS-CoV-2 particle, also known as novel coronavirus, the virus that causes COVID-19. The virus surface (blue) is covered with spike proteins (red) that enable the virus to enter and infect human cells. The virus that causes the disease COVID-19 is called Severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2 (here). The virus that causes the disease COVID-19 has been isolated and is named SARS-CoV-2.
Persons: Read Organizations: Handout, REUTERS, Pfizer, BioNTech, AstraZeneca, Moderna, Reuters Locations: Oxford
WHO's Tedros says concerned about perception pandemic is over
  + stars: | 2020-12-04 | by ( Reuters Staff | ) sentiment -0.98   time to read: +1 min
FILE PHOTO: Tedros Adhanom Ghebreyesus, Director General of the World Health Organization (WHO) attends a session on the coronavirus disease (COVID-19) outbreak response of the WHO Executive Board in Geneva, Switzerland, October 5, 2020. Christopher Black/WHO/Handout via REUTERSGENEVA (Reuters) - Recent progress on COVID-19 vaccines is positive but the World Health Organization is concerned this has led to a growing perception that the pandemic has come to an end, WHO Director-General Tedros Adhanom Ghebreyesus said on Friday. “Progress on vaccines gives us all a lift and we can now start to see the light at the end of the tunnel. However, WHO is concerned that there is a growing perception that the COVID-19 pandemic is over,” he said. Tedros said the pandemic still had a long way to run and that decisions made by citizens and governments would determine its course in the short run and when the pandemic would ultimately end.
Persons: Ghebreyesus, Christopher Black, Tedros Adhanom Ghebreyesus, , Tedros, Pfizer Inc’s Organizations: World Health Organization, WHO, Handout, REUTERS GENEVA, Pfizer, Pfizer Inc’s COVID Locations: Geneva, Switzerland, Britain, Wuhan, China
WHO warns against pandemic complacency amid vaccine rollout
  + stars: | 2020-12-04 | by ( Reuters Staff | ) + 0.00   time to read: +2 min
“Progress on vaccines gives us all a lift and we can now start to see the light at the end of the tunnel. However, WHO is concerned that there is a growing perception that the COVID-19 pandemic is over,” he said. Tedros said the pandemic still had a long way to run and that decisions made by citizens and governments would determine its course in the short run and when the pandemic would ultimately end. However, the WHO’s top emergency expert Mike Ryan also cautioned on Friday against complacency in the wake of vaccine roll-out, saying that although they were a major part of the battle against COVID-19, vaccines would not on their own end the pandemic. There are health systems in some countries at the point of collapse,” he said, without referring to specific countries.
Persons: Tedros Adhanom Ghebreyesus, Pfizer Inc’s, , Tedros, Mike Ryan, Ryan Organizations: World Health Organization, WHO, Pfizer, Pfizer Inc’s COVID, U.S . Food, Drug Administration, COVID Locations: GENEVA, Britain, Wuhan, China, U.S
The Moderna vaccine is stored at minus 20 degrees Celsius (-4 F), but can be kept for a month at normal refrigerator temperatures (here). Since the manufacturers do not disclose their specific formulations, it is not yet clear why Pfizer and Moderna’s mRNA vaccines require different storage temperatures. The Reuters Fact Check team previously fact-checked false social media claims that a COVID-19 vaccine involving the injection of the virus’s genetic code would genetically modify humans, visible here . Pfizer’s COVID-19 vaccine candidate is stored at minus 70 degrees Celsius because of the mRNA vaccine’s inherent instability – the very cold temperature slows down the chemical reactions that break apart RNA. Though both the Pfizer and Moderna vaccines contain synthetic genetic material, they do not genetically modify humans receiving them.
Persons: BioNTech’s, BioNTech, Sanjay Mishra, Mishra, ” Margaret Liu, Mark Lynas, Lynas, “ That’s, , Dr, Paul McCray, Read Organizations: Pfizer, Facebook, AstraZeneca, Moderna, Washington Post, Oxford University, Cancer, Vanderbilt University Medical Center, International Society for Vaccines, NPR, Cornell University’s Alliance for Science, Reuters, Pediatrics, Microbiology, Internal, University of Iowa
The cards are intended to fit into a wallet as a reminder when the second shot is due. Pfizer’s vaccine requires a second dose 21 days after the first and Moderna’s vaccine requires a second dose 28 days after the first. It's unclear whether the vaccine cards are intended only for people who get the Pfizer and Moderna shots. Not a vaccine passportThese vaccine cards are not intended to be used as a vaccine passport to get into bars, restaurants or airports. “Given the fact that we're in a pandemic and the seriousness of it, I don't know how much people will really need to be reminded about the second dose.”
Persons: Mike Pence, Tan, Johnson, ” Tan, Jason Hove, , Organizations: Centers for Disease Control, Department of Defense, Coalition, Food and Drug Administration, Pfizer, Moderna, UCLA Health Locations: Memphis , Tennessee
California Governor Gavin Newsom, also a Democrat, said on Thursday he would impose similar stay-at-home orders statewide, to take effect region-by-region as intensive care beds reach capacity. More than 213,830 new cases and 2,861 deaths were reported on Thursday, according to a Reuters tally of official data. With U.S. COVID-19 hospitalizations also at record levels, some experts project the death toll could soon surpass 3,000 per day. But it will fall far short of protecting high priority groups such as healthcare workers, a Reuters analysis has found. Slideshow ( 5 images )“We really have to intensify our public health measures,” Fauci, director of the National Institute of Allergy and Infectious Diseases, told NBC’s “Today” show.
Persons: Mayor London Breed, Gavin Newsom, Breed, you’re, , Newsom, Stephen Hahn, , ” Hahn, Josh Michaud, Anthony Fauci, ” Fauci, NBC’s, Fauci, Joe Biden’s, Biden, Donald Trump, I’m, ” Biden, Bill Clinton, George W, Bush, Barack Obama Organizations: ANGELES, Reuters, Friday, Mayor London, , U.S, University of Washington’s Institute for Health Metrics, Pfizer Inc, Moderna, U.S . Food, Drug Administration, Department of Defense, White, National Institute of Allergy, Democrat, CNN Locations: San Francisco, U.S, California, Bay, Napa County
LONDON — Hollywood actor Letitia Wright has triggered a wave of criticism from fans and followers after sharing anti-vaccination propaganda. Wright, who starred alongside the late Chadwick Boseman in the hit 2018 "Black Panther" movie,on Thursday posted a video on Twitter that makes unsubstantiated claims about coronavirus vaccines. The video Wright shared included a long monologue by Tomi Arayomi, a founder of a Christian ministry. Only 42 percent of Americans said "yes" to whether they'd get a Covid-19 vaccine when available, according to an August YouGov poll. Last month, eight prominent Black doctors wrote a "love letter to Black America" to encourage people to get the Covid-19 vaccine and overcome vaccine hesitancy and distrust.
Persons: Letitia Wright, Wright, Chadwick Boseman, Don Cheadle, I'm, Tomi Arayomi, Arayomi, BioNTech, they'd Organizations: NBC, Twitter, Pfizer, Blacks, Centers for Disease Control, BAFTA, Reuters Locations: Guyanese, U.S, United Kingdom, Covid, Black, Shuri
WASHINGTON (Reuters) - The U.S. Food and Drug Administration (FDA) expects to move quickly after a Dec. 10 review of the coronavirus vaccine developed by Pfizer and 20 million Americans could be vaccinated this year, its commissioner said on Friday. FILE PHOTO: FDA Commissioner Stephen Hahn testifies at the U.S. Capitol in Washington, D.C., U.S., September 23, 2020. As soon as the FDA approves a vaccine, “I will be first in line and I will encourage my family to take this vaccine,” Hahn told Reuters in an interview. Many federal officials are expecting a vaccine approval within days of the Dec. 10 meeting, though one FDA official recently said an approval decision could take weeks. Hahn said he has not made any plans about his next job after the presidential transition.
Persons: Stephen Hahn, Graeme Jennings, BioNTech, ” Hahn, Mark Meadows, Hahn, Joe Biden, , Donald Trump, Pfizer’s, Biden, COVID, Jeff Zients Organizations: WASHINGTON, U.S . Food, Drug Administration, Pfizer, U.S, Capitol, Washington , D.C, FDA, Reuters, Department of Health, Human Services, Obama, Politico Locations: U.S, Washington ,, Britain, United States
WASHINGTON (Reuters) - The U.S. Food and Drug Administration’s chief had a “robust discussion” with the White House this week about the timeline for coronavirus vaccine approvals and believes vaccinating 20 million Americans this year is realistic, he said on Friday. Many federal officials are expecting a vaccine approval within days of a Dec. 10 meeting of experts, though one FDA official recently said an approval decision could take weeks. Hahn said Biden’s team had not been in touch with him but he would be happy to provide information about the vaccine approval process. A single shot vaccine would be much easier to manage because it would not require millions of Americans to return for a second shot weeks later, a major logistical challenge for public health officials. A speedy vaccine approval could be a political win for Trump’s outgoing administration, which has been pushing for effective treatments to help restore a sense of normality to daily life and a hard-hit U.S. economy.
Persons: Stephen Hahn, Hahn, Britain, Pfizer’s, Donald Trump, Mark Meadows, Meadows, ” Hahn, , Graeme Jennings, ” Trump, Joe Biden, Biden’s, Biden, BioNTech, Johnson, Organizations: WASHINGTON, U.S . Food, Drug, Pfizer, FDA, Reuters, U.S, Capitol, Washington , D.C, Republican, Moderna Locations: U.S, United States, Washington ,
In a series of interviews, Fauci questioned the level of scrutiny the British regulators had given the authorization process of the Pfizer and BioNTech vaccine, which was approved for widespread use in the U.K. on Wednesday. Fauci even suggested that the process had been rushed after Britain became the first nation to formally approve the vaccine. The U.K.'s Medicines and Healthcare products Regulatory Agency, or MHRA, defended its approach to the vaccine in a statement issued Friday. Stephen Evans, a professor of Pharmacoepidemiology at London School of Hygiene and Tropical Medicine, said he thought Fauci had “over-stated” concerns about the U.K. assessment process of the Pfizer, BioNTech vaccine. Fauci’s comments landed as some British officials pointed to the vaccine rollout as a sign the U.K. superiority.
Persons: Anthony Fauci, Fauci, , Raine, Stephen Evans, Gavin Williamson, Matt Hancock, Alok Sharma, Andreas Michaelis, ” “, ” Michaelis, BioNTech Organizations: LONDON, Pfizer, National Institute of Allergy, Diseases, Sky News, U.S . Food, Drug Administration, NBC, FDA, British, . Department of Health, Social Care, Medicines, Healthcare, Agency, London School of Hygiene, U.K, Science Media, BBC, State for Education, LBC, European Union, Twitter, Associated Press Locations: Britain, U.S, United States, France, Belgium
U.S. expert Fauci backtracks on criticism of UK on vaccine: NBC
  + stars: | 2020-12-04 | by ( Reuters Staff | ) sentiment -0.99   time to read: +1 min
Slideshow ( 3 images )WASHINGTON (Reuters) - U.S. infectious disease expert Anthony Fauci said on Friday he was reacting to gloating by a British television interviewer when he criticized the country’s quick approval of the first coronavirus vaccine. Fauci, longtime director of a leading U.S. government health agency and member of the White House coronavirus task force, apologized for his comments late on Thursday. British regulators approved the Pfizer Inc vaccine against COVID-19 on Wednesday, saying it had rigorously assessed the vaccine data and had cut no corners. They know what they’re doing -- I mean they’re really pros, so that was just not really what I meant,” Fauci said. Fauci, director of the National Institute for Allergy and Infectious Diseases, has been asked by President-elect Joe Biden to remain in that post and also be his chief medical adviser
Persons: Anthony Fauci, , ” Fauci, NBC’s, Fauci, Joe Biden Organizations: White, Pfizer Inc, COVID, BBC, National Institute for Allergy Locations: WASHINGTON, British, U.S
The energy sector remains down 37% this year, even as a 13.5% rise has sent the S&P 500 to fresh records. (Graphic: US energy shares vs broad stock market )Hopes of an economic rebound have drawn plenty of attention to the battered sector. Goldman Sachs, Credit Suisse and Barclays in November all upgraded their ratings on the energy sector to market-weight or neutral. The relatively high dividends of many energy stocks also could draw investors, said Robert Pavlik, senior portfolio manager at Dakota Wealth Management. Still, many are worried that energy stocks could weigh on portfolio performance in the years ahead.
Persons: “ It’s, , Doug Cohen, Refinitiv Datastream, Stewart Glickman, Goldman Sachs, Savita Subramanian, Robert Pavlik, Morgan Stanley, Rob Lutts, , ” Lutts Organizations: YORK, Energy, COVID, Pfizer Inc, BioNTech, Pfizer, Moderna Inc, AstraZeneca, Exxon Mobil Corp, Chevron Corp, Occidental Petroleum Corp, Devon Energy Corp, CFRA Research, Credit Suisse, Barclays, BofA, Dakota Wealth Management, BMO Capital Markets, Cabot Wealth Management, Generac Holdings Inc Locations: U.S, United States
The first shipment is expected to cover inoculations of 3.2 million people, nowhere near enough for the 21 million U.S. healthcare workers. That means some states’ health workers will be better protected than others. The approach would initially leave out around 190,000 healthcare workers in Alabama and more than 570,000 in Illinois, according to Kaiser Family Foundation data on healthcare workers by state. “We want to ensure our hospital capacity as much as possible through vaccination for those healthcare workers who are at highest risk for infection,” she said. New York state will receive 170,000 shots initially, enough for roughly 13% of its healthcare workers.
Persons: Yves Herman, Pfizer Inc’s, , Josh Michaud, Kaiser’s, Alan Morgan, Jennifer Dillaha Organizations: YORK, Department of Defense, Pfizer, REUTERS, Pfizer Inc’s COVID, U.S . Food, Drug Administration, of Defense, State, Veterans Health Administration, Moderna Inc, Department of Health, Human Services, Federal, Reuters, U.S . Centers for Disease Control, Prevention, Pentagon, Family, Moderna, BioNTech, CDC, STATES PLAN, National Rural Health Association Locations: Puurs, Belgium, U.S, Alabama, Illinois, California, United, Arkansas’s, Alabama , California, New Mexico, Wisconsin, North Dakota, New York
Futures near record highs as stimulus hopes build
  + stars: | 2020-12-04 | by ( Shriya Ramakrishnan | ) sentiment -1.00   time to read: +2 min
(Reuters) - U.S. stock index futures held near all-time highs on Friday as growing prospects for further economic stimulus and continued optimism over a COVID-19 vaccine-driven economic recovery lifted sentiment. FILE PHOTO: The Fearless Girl statue is seen as the U.S. flag covers the front facade of the New York Stock Exchange (NYSE) in New York City, New York, U.S., November 9, 2020. Growing confidence that a working COVID-19 vaccine would be administered before the end of the year has revived demand for the hardest-hit airlines and tourism stocks. ET, Dow E-minis were up 120 points, or 0.4%, and S&P 500 E-minis were up 11.25 points, or 0.31%. Drugmaker Pfizer fell 0.8%, extending declines from the previous session when it flagged challenges in supply chain for raw materials used in its COVID-19 vaccine.
Persons: Brendan McDermid, Drugmaker Organizations: Reuters, New York Stock Exchange, REUTERS, U.S, Congress, Republicans, Democrats, Labor, American Airlines, Cruise, Carnival Corp, Dow E, Nasdaq, Drugmaker Pfizer, Oil, Exxon Mobil Corp, Chevron Corp Locations: U.S, New York City , New York
How to Handle the Covid-19 Vaccine Breakthrough the Right Way
  + stars: | 2020-12-04 | by ( Tom Frieden | ) + 0.00   time to read: +17 min
If Covid-19 vaccines were only 70% effective, a vaccine taken by 70% of people would protect roughly half of society. At 70% uptake (and combined with the immunity of unvaccinated people who have recovered from the virus), vaccination could end the explosive spread of the virus. A researcher works in a lab run by Moderna Inc., which said last month that its Covid-19 vaccine was more than 90% effective, based on interim data from a late-stage clinical trial. ”No serious adverse events have been identified among the tens of thousands of participants in clinical trials of the leading Covid-19 vaccines. Related Video The U.K. granted emergency-use authorization for Pfizer and BioNTech’s Covid-19 vaccine and could begin distribution to the most vulnerable populations within days.
Persons: I’m, SANDY HUFFAKER, Johnson, Alex Kraus, Craig F, Walker, BioNTech’s, Gavi, won’t, Covid, Dr, Frieden Organizations: Moderna Inc, Pfizer Inc, AstraZeneca, University of Oxford, Covid, REUTERS, Centers for Disease Control, Pfizer, Moderna’s, Trump, Getty, Employees, Bloomberg, CDC, Residents, Boston Globe, University of Maryland School of Medicine, AP, World Health Organization, Coalition for, Preparedness, Council, Foreign Relations Locations: U.S, Europe, Covid, San Diego, AFP, Wurzburg, Germany, Boston, Covax
Norway to use three vaccines to stop COVID-19 from early 2021
  + stars: | 2020-12-04 | by ( Gwladys Fouche | Victoria Klesty | ) sentiment -0.99   time to read: +2 min
OSLO (Reuters) - Norway plans to use the three vaccines developed by Moderna, AstraZeneca, Pfizer and BioNTech in its first push to inoculate its population against COVID-19, Norway’s health minister said on Friday. FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. Norway is proceeding faster than earlier announced; Prime Minister Erna Solberg said in October she expected vaccinations to start in the first half of 2021. Britain on Wednesday became the first nation in the Western world to approve a COVID-19 vaccine, the one developed by Pfizer and BioNTech. (GRAPHIC: Norway weekly COVID-19 infections - )The number of infections has slowed in recent weeks after the government reintroduced restrictions a month ago.
Persons: Dado Ruvic, Bent Hoeie, ” Hoeie, Erna Solberg Organizations: Moderna, AstraZeneca, Pfizer, BioNTech, REUTERS, Health, Union, Britain, Wednesday, European Centre for Disease Prevention Locations: OSLO, Norway, COVID, Oslo, EU Norway, Sweden, Europe, Iceland, Ireland, Finland
TORONTO (Reuters) - The outlook for the Canadian dollar has improved on expectations the currency will benefit from domestic economic stimulus and the rollout of a COVID-19 vaccine, a Reuters poll showed, with the loonie already gaining in recent months. FILE PHOTO: A Canadian dollar coin, commonly known as the "Loonie", is pictured in this illustration picture taken in Toronto January 23, 2015. REUTERS/Mark Blinch/File PhotoCanada’s dollar has strengthened 14% against its U.S. counterpart since March, reaching a two-year high on Thursday at 1.2848 per U.S. dollar, or 77.83 U.S. cents. “We see several tailwinds for the Canadian dollar,” said Stephen Brown, senior Canada economist at Capital Economics. Still, Harvey expects a high savings rate and strong vaccination orders, along with fiscal stimulus, to support economic recovery.
Persons: Mark Blinch, , , Stephen Brown, Chrystia Freeland, Brown, Simon Harvey, Harvey Organizations: TORONTO, REUTERS, U.S, Capital Economics, Canadian Finance, Monex, Pfizer Locations: Toronto, Canada, COVID, Monex Canada
BEIJING (Reuters) - Two coronavirus vaccine candidates developed by China’s Clover Biopharmaceuticals triggered strong immune responses in an early-stage human trial and appeared to be safe, the company said on Friday. REUTERS/Dado Ruvic/IlustrationThe vaccine candidates, one containing an adjuvant from GlaxoSmithKline and the other from Dynavax, induced strong immune responses including neutralizing antibodies and cell-mediated immunity in a Phase 1 clinical trial, Clover said. “Based on the positive Phase 1 results reported and the unprecedented need for COVID-19 vaccines, Clover and its partners are confident to enter late-stage clinical development for both adjuvanted vaccines,” the company said. Britain approved Pfizer Inc’s COVID-19 vaccine on Wednesday, jumping ahead in a global race to begin the most crucial mass inoculation programme in history. AstraZeneca Plc, Moderna Inc, and Russian researchers have also announced positive trial results in recent weeks.
Persons: China’s Clover, Dado Ruvic, Clover, Pfizer Inc’s Organizations: REUTERS, GlaxoSmithKline, Pfizer, Pfizer Inc’s COVID, AstraZeneca, Moderna Inc, Coalition for Locations: BEIJING, Britain
Energy stocks drive gains in European shares
  + stars: | 2020-12-04 | by ( Susan Mathew | ) sentiment -0.98   time to read: +2 min
(Reuters) - Oil stocks lifted European shares on Friday, with London’s blue-chip index hitting nine-month highs, while signs of progress in fiscal stimulus in the United States also aided sentiment. FILE PHOTO: The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, November 26, 2020. REUTERS/StaffLondon FTSE 100 rose 0.8% as crude prices gained after a compromise between OPEC+ members to continue some production cuts. “As long as a basic deal is struck that avoids a no-deal scenario, that would help sentiment,” Madden said. Shares of UK homebuilder Berkeley lost 2.8% after it reported a 16.6% fall in first-half profit as home sales were dented by the pandemic.
Persons: , David Madden, ” Madden, DAX, BioNtech Organizations: Reuters, REUTERS, Staff London, Nasdaq, U.S . Congress, CMC, European Union, Pfizer, homebuilder Berkeley Locations: United States, Frankfurt, Germany, London, Europe’s
MOSCOW (Reuters) - Muscovites from high-risk groups such as healthcare workers began registering for jabs of a Russian-made COVID-19 vaccine on Friday, two days after President Vladimir Putin called for large-scale vaccinations. REUTERS/Alexey MalgavkoSputnik V, one of two Russian-made vaccines to have received regulatory approval in Russia despite clinical trials being incomplete, requires two injections. Britain is preparing in the coming days to launch its own mass innoculation programme after becoming the first country worldwide to approve Pfizer Inc’s COVID-19 vaccine. The decision to take part in Russia’s vaccine trials is voluntary, authorities say, but some public sector workers have told Reuters of pressure to take part. Russia has so far recorded 2,402,949 COVID-19 infections, taking fourth place globally behind only the United States, India and Brazil.
Persons: Vladimir Putin, Alexey Malgavko Sputnik, Sergei Sobyanin, Kirill Dmitriev, Pfizer Inc’s, Anna Popova, , Igor Krivobokov, Sergei Grishin Organizations: REUTERS, Sputnik, BBC, European Union, European Medicines Agency, Pfizer, Pfizer Inc’s COVID, TASS Locations: MOSCOW, Russian, Omsk, Russia, COVID, Moscow, Hungary, United States, India, Brazil
stock futures edged higher Friday as investors watched the Senate make progress on fiscal stimulus talks. Futures tied to the S&P 500 rose 0.3%, indicating muted gains in the broader gauge after the New York opening bell. Market Movers to Watch—DocuSign rose 4.7% premarket after the maker of e-signature software reported better-than-expected third-quarter revenue. Projections for the current quarter mostly missed Wall Street targets as the company pointed to supply challenges. —Pfizer fell 0.8% premarket.
Persons: Organizations: Nasdaq, Seer Inc, Silverback Therapeutics, Sigilon Therapeutics, Movers, Marvell Technology, — Pfizer Locations: York
Costa Rica signs COVID-19 vaccine deal with Pfizer and BioNTech
  + stars: | 2020-12-04 | by ( Reuters Staff | ) sentiment -0.98   time to read: +1 min
FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Pfizer logo in this illustration taken October 31, 2020. REUTERS/Dado RuvicSAN JOSE (Reuters) - Costa Rica has signed an agreement with pharmaceutical companies Pfizer Inc and its German partner BioNTech SE for the manufacture and delivery of 3 million COVID-19 vaccines next year, the office of President Carlos Alvarado said on Thursday. The deal will allow Costa Rica to provide two doses to 1.5 million people and follows accords with AstraZeneca and the Covax mechanism backed by the World Health Organization. In total, the agreements should cover about 3 million people, or almost 60% of the Costa Rican population. The Central American country has so far registered some 142,505 cases of coronavirus and 1,757 related deaths.
Persons: Carlos Alvarado Organizations: Pfizer, REUTERS, Pfizer Inc, AstraZeneca, World Health Organization, Central Locations: Costa Rica, Costa Rican
Asia-Pacific stocks trade mixed amid Covid vaccine concerns
  + stars: | 2020-12-04 | by ( Eustance Huang | ) sentiment -1.00   time to read: +1 min
SINGAPORE — Stocks in Asia-Pacific were mixed in Friday morning trade after a report said Pfizer expects to ship half the Covid-19 vaccine doses it originally planned for this year due to supply chain issues. In Japan, the Nikkei 225 dipped 0.23% in early trade while the Topix was slightly lower. Reuters reported, citing sources, JD Logistics is seeking bank pitches for a Hong Kong IPO of up to $3 billion. The development came just days after's digital health-care unit, JD Health, raised $3.5 billion in a Hong Kong IPO. Shares of JD Health are expected to begin trading on Tuesday.
Organizations: Pfizer, Nikkei, Australia, Japan, Reserve Bank of, Reuters, JD Logistics, Hong, JD, JD Health Locations: SINGAPORE, Stocks, Asia, Pacific, Japan, Reserve Bank of India, Hong Kong
Former FDA Chief and Pfizer board member Dr. Scott Gottlieb told CNBC that he is "hopeful" there will be adequate vaccine supply in 2021, on the heels of a Wall Street Journal report that Pfizer had to cut its original estimates for the amount of vaccine doses this year because of supply-chain problems. "The supply ramps very quickly as you move out and the more you push out that timeframe into 2021 by a week or two weeks, you have less supply in 2020," Gottlieb said. "I'm hopeful that we're going to have adequate supply in 2021 and it's going to ramp very quickly, but hopefully these do get into the market this year." One American died about every 30 seconds from Covid on Wednesday, according to a CNBC analysis of Johns Hopkins data. Gottlieb said that while there is some protection after the first dose, both doses should be taken for 95% efficacy.
Persons: Scott Gottlieb, Gottlieb, Johns, Johns Hopkins, Hospitalizations, Covid, Bruce Becker, Becker, Shepard Smith, BioNTech, Smith, that's Organizations: FDA, Pfizer, CNBC, Journal, Brown University's School of Public Health, for Disease Control, Prevention, Moderna Locations: Covid, Johns Hopkins, United States
Gold on track for weekly gain as U.S. stimulus hopes dent dollar
  + stars: | 2020-12-04 | by ( ) sentiment -0.99   time to read: +2 min
Gold prices firmed on Friday, set for their first weekly gain in four, as growing optimism over a U.S. fiscal stimulus deal pressured the dollar and boosted the metal's appeal as an inflation hedge. Spot gold rose 0.2 % to $1,843.99 per ounce by 0310 GMT. The U.S. dollar eased on Friday and was set for its worst week since early November, making gold cheaper for other currency holders. Also supporting gold was news that drugmaker Pfizer slashed its target for the rollout of its Covid-19 vaccine on supply disruptions. Silver rose 0.1% to $24.09 per ounce and was set to climb 6% in the week.
Persons: Margaret Yang, Yang Organizations: U.S . Federal Reserve, U.S, Congress, Pfizer, Fitch Solutions Locations: SA, Lugano, Switzerland
Total: 25